For the full disclaimer wording see BMJ's terms and conditions: Sheyu Li, endocrinologist, clinical chair12, Per Olav Vandvik, methodologist, internist34, Lyubov Lytvyn, methodologist5, Gordon H Guyatt, methodologist, internist56, Suetonia C Palmer, nephrologist7, Ren Rodriguez-Gutierrez, endocrinologist8910, Farid Foroutan, methodologist11, Thomas Agoritsas, methodologist, internist12, Reed A C Siemieniuk, methodologist, internist56, Michael Walsh, nephrologist, methodologist56, Lawrie Frere, general practitioner13, David J Tunnicliffe, research fellow1415, Evi V Nagler, nephrologist16, Veena Manja, cardiologist17, Bjrn Olav svold, endocrinologist1819, Vivekanand Jha, nephrologist2022, Mieke Vermandere, general practitioner23, Karim Gariani, internist12, Qian Zhao, general practitioner24, Yan Ren, endocrinologist1, Emma Jane Cartwright, UK patient editor25, Patrick Gee, patient partner26, Alan Wickes, patient partner27, Linda Ferns, patient partner27, Robin Wright, patient partner27, Ling Li, methodologist2, Qiukui Hao, geriatrician, methods chair528, Reem A Mustafa, nephrologist, methodologist, clinical chair529 1 Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China 2 Chinese Evidence-based Medicine Center, Cochrane China Center and MAGIC China Center, West China Hospital, Sichuan University, Chengdu, China 3 University of Oslo, Oslo, Norway 4 MAGIC Evidence Ecosystem Foundation 5 Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada 6 Department of Medicine, McMaster University, Hamilton, ON, Canada 7 Department of Medicine, University of Otago, Christchurch, New Zealand 8 Plataforma INVEST Medicina UANL KER Unit (KER Unit Mxico), Subdireccin de Investigacin, Universidad Autnoma de Nuevo Len, Monterrey, 64460, Mxico 9 Knowledge and Evaluation Research Unit in Endocrinology, Mayo Clinic, Rochester, MN, 55905, USA 10 Endocrinology Division, Department of Internal Medicine, University Hospital Dr

Injection Site Selection For subcutaneous injections, common sites include the abdomen at least two inches from the navel, front and outer thighs, and back of upper arms
1 The global anti-obesity drug market is expected to reach $82.55 billion (USD) by 2032, driven by a compound annual growth rate (CAGR) of 18.01% from 2025 to 2032
With bellwether trials nearing and courts steadily clarifying liability standards, 2026 is emerging as a pivotal year for Ozempic and the broader GLP-1 litigation landscape
Weight-loss drug makers announce pricing agreement with Trump The deal, which includes Eli Lilly and Novo Nordisk, will slash prices for Medicare and Medicaid programme recipients
Frequently Asked Questions Can I use sterile water instead of bacteriostatic water for IGF-1 LR3